B7-H3-Targeted Smart Drug for Metastatic Prostate Cancer: Phase 3 BNT324-03 Trial Has Begun in Turkey

In this article
A B7-H3-Targeted ADC Against Docetaxel in Castration-Resistant Prostate Cancer: BNT324-03
BNT324 (DB-1311, elfetabart drozuntecan), a B7-H3-targeted antibody-drug conjugate developed by BioNTech together with DualityBio, is being compared with the standard chemotherapy docetaxel in metastatic castration-resistant prostate cancer (mCRPC). The randomized phase 3 BNT324-03 trial, registered on ClinicalTrials.gov as NCT07365995, covers about 736 patients and began in April 2026. In Turkey the trial is ready to open at 15 centers; the first patients are expected in mid-December, with a total of 54 patients from our country planned. The Memorial Göztepe Hospital Cancer Center, where I work, will be one of the centers running this clinical trial in Turkey. In this article I explain how BNT324 works, what the early-phase results showed, how the trial is designed and which patients may be eligible. I covered today's options in advanced prostate cancer in advanced prostate cancer treatment, the biology of B7-H3 in What is B7-H3? and antibody-drug conjugates in What is an ADC? (all in Turkish).
- What is being studied? In patients with metastatic prostate cancer who progressed after 1 or 2 ARPIs (abiraterone, enzalutamide, apalutamide, darolutamide) and have had no chemotherapy in the castration-resistant setting, BNT324 (6 mg/kg every 3 weeks) is compared 1:1 with docetaxel plus prednisone/prednisolone.
- Primary endpoints: Radiographic progression-free survival and overall survival. Prior Lu-PSMA and prior docetaxel in the hormone-sensitive setting do not exclude patients.
- Early data: In the phase 1/2 study in heavily pretreated patients, the confirmed response rate was 30.8% and disease control 90.4%; in a 146-patient update, median radiographic progression-free survival was 11.3 months and median overall survival 22.5 months. With no control arm, these data are a signal, not proof.
- Turkey: From mid-December 2026, about 54 patients are planned at 15 centers, including the Memorial Göztepe Hospital Cancer Center. Patients who think they may be eligible should talk to their oncologist.
Why does this matter?
Prostate cancer is one of the most common cancers in men. When the disease reaches the metastatic stage it first responds to hormone therapy, but over time it starts to progress even though testosterone is suppressed. This stage is called metastatic castration-resistant prostate cancer (mCRPC) (prostate cancer stages and treatment). In recent years the most effective drugs have moved to earlier stages: in newly diagnosed metastatic disease, ARPIs, docetaxel in suitable patients and even lutetium-PSMA are now used up front (which treatment for newly diagnosed stage 4?, PSMAddition; both in Turkish). This leaves fewer options once the disease becomes resistant.
Today's options in the castration-resistant stage are docetaxel and cabazitaxel chemotherapy, lutetium-PSMA in PSMA-positive patients, PARP inhibitors in those with BRCA or other DNA-repair gene alterations, and radium-223 in bone-predominant disease (lutetium therapy, PARP inhibitors in prostate cancer; both in Turkish). But PSMA is not high enough in every patient, the share of patients with a genetic alteration is limited, and many patients do not want or cannot tolerate chemotherapy. In the VISION trial, even in the lutetium-PSMA arm, median overall survival was 15.3 months. That is why the need for new targets and for treatments better tolerated than chemotherapy is so great.
Figure 1 · The disease journey in metastatic prostate cancer
Options and unmet need in the castration-resistant stage
- Yes: For Turkey, BNT324 is the first B7-H3-targeted ADC to be used in our country at the phase 3 level. The trial is this drug's first phase 3 trial in prostate cancer.
- No: It is not the first B7-H3 ADC compared with docetaxel in prostate cancer. The phase 3 IDeate-Prostate01 trial with ifinatamab deruxtecan (I-DXd) began in 2025 and covers about 1440 patients.
- Not yet: There is no approved B7-H3-targeted drug in prostate cancer. In June 2024 BNT324 received FDA Fast Track designation for previously treated mCRPC; that is not an approval.
What is BNT324?
BNT324 (DB-1311, elfetabart drozuntecan) is an antibody-drug conjugate in which an antibody that binds the B7-H3 protein on the surface of tumor cells carries a topoisomerase-I inhibitor chemotherapy payload. It acts by delivering the drug directly inside the tumor cell. It is not yet approved in any country; it is being studied in a randomized phase 3 trial in metastatic prostate cancer.
B7-H3 (CD276) is a protein from the same family as PD-L1 that suppresses the immune response. It is present at high levels in many solid tumors but at limited levels in most healthy tissues. In prostate cancer this feature is even more pronounced: in a study published in European Urology in 2023 by de Bono and colleagues from the Royal Marsden and the Institute of Cancer Research, high B7-H3 expression was found in more than 90% of primary and metastatic prostate cancers. B7-H3 can also stay high in tumors with low PSMA, which is an important advantage for patients who are not suitable for lutetium-PSMA. Because the expression is so widespread, no B7-H3 test is needed to enter the trial.
Figure 2 · How does BNT324 work?
The four steps of an antibody-drug conjugate
This mechanism is an approach I know from drugs such as trastuzumab deruxtecan (Enhertu) in breast cancer (trastuzumab deruxtecan; in Turkish). B7-H3-targeted ADCs have given striking results over the past two years, especially in small cell lung cancer; I described the lung cancer data for BNT324 in the article on pumitamig and elfetabart drozuntecan and ifinatamab deruxtecan, which uses the same target, in this article (both in Turkish).
What did the early-phase studies show?
The basis for moving BNT324 into phase 3 is the phase 1/2 study (NCT05914116) conducted in different cancer types. In the first prostate cancer data presented at ASCO in June 2025, 73 patients with mCRPC were treated at 6 or 9 mg/kg. The patients were heavily pretreated: the median number of prior therapies was 4. In the 52 evaluable patients, the confirmed response rate was 30.8% and the disease control rate 90.4%; about two thirds of patients were progression-free at 6 months. Similar results were obtained at the two dose levels.
In the update presented at ASCO GU in February 2026, the number of patients rose to 146 (data cutoff December 29, 2025). Median radiographic progression-free survival was reported as 11.3 months and median overall survival as 22.5 months. Efficacy continued in patients who had received lutetium-PSMA before. At the 6 mg/kg dose used in phase 3, the rate of treatment-related adverse events of grade 3 or higher was 20% and the rate of discontinuation because of adverse events was 5.5%; no treatment-related loss of life was reported.
BNT324 in the phase 1/2 study: key rates
Heavily pretreated mCRPC; ASCO 2025 (data cutoff March 4, 2025) and ASCO GU 2026 data. Percent of patients.
These are phase 1/2 data without a control arm; cross-study comparisons cannot be made. In the ASCO GU 2026 update (146 patients, data cutoff December 29, 2025), median radiographic progression-free survival was 11.3 months and median overall survival 22.5 months. Source: DualityBio announcements.
These results point to meaningful activity even after many prior treatments. But data from a phase 1/2 study without a control arm, in selected patients, do not prove that the drug is better than standard treatment (what is a clinical trial?; in Turkish). Only randomized phase 3 trials such as BNT324-03 can show that.
Design of the BNT324-03 trial
Patients enrolled in the trial are randomly divided into two equal groups. One group receives BNT324 6 mg/kg intravenously every 3 weeks; treatment continues until the disease progresses or unacceptable side effects develop. The other group receives docetaxel every 3 weeks together with prednisone or prednisolone 5 mg twice daily; docetaxel is given for at most 10 cycles (docetaxel in prostate cancer; in Turkish). Androgen deprivation therapy continues in both groups. The trial is open-label, meaning the patient and the physician know which treatment is given.
Figure 3 · Design of the BNT324-03 trial
Phase 3, randomized (1:1), open-label
The primary endpoints are radiographic progression-free survival by independent central review and overall survival. Secondary endpoints include response rate, duration of response, PSA response, time to pain progression, bone-related events, quality of life and safety. The primary completion date of the trial is projected for February 2031.
Who may be eligible?
According to the registered protocol, the main inclusion criteria are:
- Age 18 or older, pathologically confirmed metastatic prostate adenocarcinoma.
- Documented progression of PSA, soft tissue or bone while testosterone is at castration level (below 50 ng/dL).
- Prior treatment with 1 or 2 ARPIs (abiraterone, enzalutamide, apalutamide or darolutamide) and progression during or after at least 8 weeks of therapy.
- No chemotherapy, including taxanes, in the castration-resistant setting; docetaxel in the hormone-sensitive setting does not exclude.
- Able to carry out daily activities independently or with mild limitation (ECOG 0-1).
Patients who have previously received a B7-H3-targeted therapy, those with uncontrolled serious cardiovascular disease, and those with a history of non-infectious lung inflammation requiring steroids (interstitial lung disease or pneumonitis) cannot be enrolled. Exact eligibility is determined by tests during the screening period and by central review.
Two phase 3 trials on the same target: BNT324-03 and IDeate-Prostate01
Two large phase 3 trials will determine the place of B7-H3-targeted ADCs in prostate cancer. Both compare with docetaxel in patients with mCRPC after an ARPI who have had no chemotherapy, and in both overall survival is a primary endpoint. This shows how fast the field is moving, but there is no direct comparison between the two drugs.
| Feature | BNT324-03 | IDeate-Prostate01 |
|---|---|---|
| Drug | BNT324 (DB-1311) | Ifinatamab deruxtecan (I-DXd) |
| Number of patients | About 736 | About 1440 |
| Dose | 6 mg/kg every 3 weeks | 12 mg/kg every 3 weeks |
| Comparator | Docetaxel + prednisone/prednisolone | Docetaxel + prednisone |
| Primary endpoint | rPFS and overall survival | Overall survival and rPFS |
| Start | April 2026 | 2025 |
Side effects and safety monitoring
In early-phase studies the most common side effects of BNT324 were digestive complaints such as nausea, loss of appetite and fatigue, and drops in blood counts such as anemia and low white cell and platelet counts; most were mild or moderate. Drops in blood counts were more frequent at the 9 mg/kg dose; the 6 mg/kg dose was chosen for phase 3.
As with all ADCs carrying a topoisomerase-I inhibitor payload, non-infectious lung inflammation (interstitial lung disease) is a class risk that must be watched closely. New or worsening cough, shortness of breath and fever should be reported to the physician right away. When recognized early, it can often be controlled by pausing treatment and giving corticosteroids. For this reason lung symptoms and imaging are monitored regularly in the trial.
The situation in Turkey and what it means in practice for patients
For the Turkish arm of the trial, 15 centers are ready, including the Memorial Göztepe Hospital Cancer Center, where I work; the first patients are expected to be enrolled around mid-December 2026, with a total of 54 patients from our country planned. Because some patients will not meet the criteria during screening, the number of patients evaluated will be much larger. Outside the trial, BNT324 is not available in Turkey or in any other country.
I also want to stress that this trial is not suitable for every patient. In every patient with castration-resistant disease, genetic tests (hereditary and tumor HRR/BRCA tests), PSMA imaging and the biological features of the tumor should be evaluated first (genetic tests in stage 4, hereditary prostate cancer test; both in Turkish). PARP inhibitors in patients with BRCA alterations and lutetium-PSMA in PSMA-positive patients are proven options (olaparib and abiraterone, Pluvicto or ARPI?; both in Turkish). When chemotherapy becomes necessary, a clinical trial offers the patient a chance to access a new drug in addition to standard treatment; but no one can choose the result of randomization, and half of the patients receive standard docetaxel (why do clinical trials matter?; in Turkish).
Other approaches such as immunotherapy and radioligand combinations are also being investigated in prostate cancer (the PRINCE trial; in Turkish). The national roadmap prepared in our country for newly diagnosed metastatic prostate cancer also shows that treatment is becoming ever earlier and more personalized (the roadmap of Turkish oncologists, Pluvicto now earlier; both in Turkish).
Questions you can ask your doctor
- Is my disease in the castration-resistant stage, and do my testosterone level and signs of progression confirm it?
- Which treatments do my hereditary and tumor genetic tests (BRCA, HRR) and my PSMA PET result bring into consideration?
- If chemotherapy is needed, could a clinical trial like BNT324-03 be suitable for me?
- If I take part, which treatments could I receive depending on randomization, and how often would I need to come for checks?
- Regarding lung side effects, which symptoms should make me contact you right away?
- “If I join a clinical trial, I will definitely get the new drug.” No. By randomization, half of the patients receive BNT324 and half receive standard docetaxel; you cannot choose which group you end up in.
- “Patients in clinical trials are like laboratory animals.” No. Phase 3 trials are run with ethics committee and Ministry of Health approval and strict safety monitoring; the control group also receives proven standard treatment, and a patient can leave the trial at any time.
- “I need to have a B7-H3 test.” No. Because B7-H3 is high in more than 90% of prostate cancers, no separate B7-H3 test is required to enter the trial.
- “If I have had lutetium-PSMA, I am no longer eligible.” No. Prior lutetium-PSMA does not prevent participation in this trial.
- “ADCs are not chemotherapy and have no side effects.” No. ADCs carry a chemotherapy payload; drops in blood counts, nausea and, rarely, serious lung inflammation can occur.
Frequently Asked Questions
- What is BNT324?
- BNT324 (DB-1311, elfetabart drozuntecan) is an antibody-drug conjugate that binds the B7-H3 protein on tumor cells and delivers a chemotherapy payload directly to the tumor cell. It is not yet approved; it is being studied in a phase 3 trial in prostate cancer.
- Who can take part in the BNT324-03 trial?
- Patients with metastatic prostate cancer who progressed after 1 or 2 ARPIs, have had no chemotherapy in the castration-resistant setting and are in good general condition may be eligible. Exact eligibility is determined by screening tests.
- Which treatments are being compared in the trial?
- BNT324 6 mg/kg intravenously every three weeks is compared with docetaxel and prednisone or prednisolone every three weeks. Hormone-suppressing therapy continues in both groups.
- When does the trial start in Turkey?
- Enrollment is planned to begin around mid-December 2026 at 15 centers, including the Memorial Göztepe Hospital Cancer Center, with a total of 54 patients. For eligibility you need to talk to your treating oncologist.
Glossary
- mCRPC
- Metastatic castration-resistant prostate cancer; spread disease that progresses despite suppressed testosterone.
- ARPI
- Androgen receptor pathway inhibitor; new-generation hormone drugs such as abiraterone, enzalutamide, apalutamide and darolutamide.
- ADT
- Androgen deprivation therapy; injections or surgery that stop testosterone production.
- B7-H3 (CD276)
- A surface protein present at high levels in many tumors that suppresses the immune response.
- Antibody-drug conjugate (ADC)
- A drug made by attaching a chemotherapy payload to an antibody that recognizes the tumor.
- Topoisomerase-I inhibitor
- A type of chemotherapy that blocks DNA copying in the cell; the payload of many new ADCs.
- Bystander effect
- Passage of the ADC payload to surrounding tumor cells that carry little of the target protein.
- Radiographic progression-free survival (rPFS)
- The time during which the disease does not progress on imaging.
- Lutetium-PSMA
- A radioligand therapy that delivers radiation to prostate cancer cells carrying PSMA.
- Interstitial lung disease
- Non-infectious inflammation of lung tissue; a known class risk of ADCs with a topoisomerase-I payload.
DROZDOGAN Academy Commentary
In castration-resistant prostate cancer, docetaxel has been the standard for more than twenty years. An ADC directly challenging this standard is an important test, both for patients and for the future of prostate cancer treatment.
⚡ Why it matters
B7-H3 is present in nearly all prostate cancers and is independent of PSMA. If phase 3 is positive, an alternative to chemotherapy could emerge for a broad group of patients without the need for biomarker selection.
✅ Strengths
Randomized design; an active, standard comparator arm; overall survival among the primary endpoints; patients with prior lutetium-PSMA not excluded; quality of life measured, and patients from Turkey able to join early.
⚠️ Limitations
The open-label design may affect side-effect and quality-of-life reporting in particular. The early-phase data come from selected patients without a control arm, and there is no peer-reviewed full publication yet. It is not known whether the B7-H3 expression level predicts response; in tumors with neuroendocrine differentiation B7-H3 may decrease.
🩺 In practice
In my castration-resistant patients I first complete genetic testing and PSMA PET and assess eligibility for a PARP inhibitor or lutetium-PSMA. When chemotherapy comes up and the patient meets the criteria, I present the clinical trial option, explaining plainly what randomization means along with the possible benefits and risks. The decision always belongs to the patient.
❓ Open questions
Will BNT324 provide longer survival than docetaxel, or a similar effect with better tolerability? Is there a meaningful difference between the two B7-H3 ADCs? What should the sequence of ADCs be (before or after lutetium-PSMA)? Can B7-H3 ADCs be combined with immunotherapy or hormone therapies?
Bottom line: BNT324-03 is a critical trial that will show the real value of the B7-H3 target in prostate cancer. The early data are promising, but the final verdict will come from randomized results. The chance for patients in Turkey to join this process early is an important opportunity.
- This article was prepared in November 2026.
- The trial design and eligibility criteria are taken from the ClinicalTrials.gov record (NCT07365995), the early-phase results from the abstract of the ASCO 2025 presentation and DualityBio announcements; the full text of the ASCO GU 2026 presentation could not be accessed. The numbers of centers and patients in Turkey are planning-stage information and may change.
- The Memorial Göztepe Hospital Cancer Center, where I work, is one of the Turkish centers of this trial; I want readers to know about this relationship.
- This article is not a patient recruitment notice; eligibility for a clinical trial can only be assessed by the treating physician and the trial team.
- The diagrams are simplified. The Academy commentary is my own. This article is not medical advice; make treatment decisions together with your physician.
References
- A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer (BNT324-03). ClinicalTrials.gov NCT07365995. clinicaltrials.gov
- BioNTech clinical trial page: BNT324-03. clinicaltrials.biontech.com
- Parsonson A, et al. DB-1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC). J Clin Oncol 2025;43(16_suppl):5015. ascopubs.org
- ASCO 2025: DB-1311/BNT324 in heavily pretreated CRPC (presentation summary). urotoday.com
- DB-1311/BNT324 in heavily pretreated mCRPC: analyses according to prior 177Lu-PSMA-617. J Clin Oncol 2026;44(7_suppl):176. ascopubs.org
- DualityBio. Preliminary data from two clinical trials with ADC candidates presented orally at the 2025 ASCO Annual Meeting. dualitybiologics.com
- BioNTech and DualityBio receive FDA Fast Track designation for BNT324/DB-1311 in mCRPC. June 2024. urologytimes.com
- Guo C, Figueiredo I, Gurel B, et al. B7-H3 as a therapeutic target in advanced prostate cancer. Eur Urol 2023;83:224-238. doi
- IDeate-Prostate01: ifinatamab deruxtecan versus docetaxel in mCRPC. ClinicalTrials.gov NCT06925737. clinicaltrials.gov
- Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer (VISION). N Engl J Med 2021;385:1091-1103. doi
- Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer (TAX327). N Engl J Med 2004;351:1502-1512. doi
Was this article helpful?
Your feedback helps us improve our content.




